Oxytocin reduces neural activation in response to infant faces in nulliparous young women

Peter A. Bos, Hannah Spencer, and Estrella R. Montoya

Experimental Psychology, Utrecht University, the Netherlands

Correspondence should be addressed to Peter A. Bos, PhD, Experimental Psychology, Utrecht University, Heidelberglaan 2 3584 CS, Utrecht, Netherlands. E-mail: p.a.bos@uu.nl.

Abstract

Infant faces have distinctive features that together are described as baby schema, a configuration that facilitates caregiving motivation and behavior, and increases the perception of cuteness. In the current functional magnetic resonance imaging (fMRI) study, we investigated the effect of a within-subjects intranasal oxytocin administration (24 IU) and caregiving motivation on neural responses to infant faces of varying baby schema in 23 healthy nulliparous women. Overall, infant faces elicited activation in several brain regions involved in reward and salience processing, including the ventral tegmental area (VTA), putamen, amygdala, anterior cingulate cortex (ACC), and insula, and this activation was related to self-reported caregiving motivation. Critically, whereas we hypothesized enhanced neural caregiving-related responses after oxytocin administration, we observed reduced activation in the VTA, putamen and amygdala after oxytocin compared to placebo. In nulliparous women, oxytocin has been shown to reduce neural responses in the same regions in response to social stimuli using other paradigms. Oxytocin might affect neural activation toward social stimuli depending on elicited arousal and personal characteristics. The current study is the first to demonstrate this effect in response to infant faces and thereby adds to specify the role of oxytocin in human social information processing.

Key words: fMRI; parental care motivation; VTA; striatum; reward; caregiving

Introduction

As proposed by Lorenz in 1943, more pronounced features characteristic of infant faces, such as a large forehead and eyes combined with a small nose, mouth, and chin, would elicit more caregiving behavior and reduce aggression toward the infant (Lorenz, 1943). Experimental work in the past decades has demonstrated that such a facial configuration, referred to as ‘baby schema’, is related to perceptions of cuteness and positive affective responses (DeBruine et al., 2016), and indeed increases caregiving behavior and motivation, both in parents and in nulliparous adults (Langlois et al., 1995; Glocker et al., 2009a; Hahn and Perrett, 2014). Neuroimaging studies have further shown that baby schema increase activation of several brain regions involved in reward processing, including the ventral tegmental area (VTA), and the ventral striatum (Glocker et al., 2009b; Feldman, 2015; Luo et al., 2015), which might underlie some of these observed behavioral responses. Importantly, the neural reward circuitry is sensitive not only to infant faces but also to endocrine factors including the neuropeptide oxytocin (OXT) that has also been ascribed an important role in the facilitation of parent–infant attachment and caregiving behavior (Rilling and Young, 2014; Bos, 2017; Feldman, 2017). Increasing activation of the neural reward circuitry in response to infant faces is one of the mechanisms by which OXT could facilitate parental caregiving. In the current study, we investigated the effect of OXT on the neural reward circuitry in a group of healthy young nulliparous women when looking at infant faces using functional magnetic resonance imaging (fMRI).
So far, a limited number of studies have directly investigated the role of OXT in neural responses to infant faces, and most of these studies were correlational studies, in which OXT levels were measured from either saliva or blood (Luo et al., 2015; Feldman, 2017). Although there is considerable discussion about the validity of these assessments (McCullough et al., 2015; Leng and Ludwig, 2016), positive relations between OXT levels and attention toward infant faces have repeatedly been found in parents (Luo et al., 2015), as well as enhanced neural reward activation toward infant faces, especially toward own infants vs other infants (Strathearn et al., 2009). An important reason to set up the current study, is that only few studies employed OXT administration paradigms. So far, in fathers, increased activation of the caudate (part of the striatum) and the anterior cingulate cortex (ACC) was observed in response to own children pictures after OXT administration (Wittfoth-Schardt et al., 2012; Li et al., 2017), although one of the two studies additionally showed a decreased activation in the more ventral part of the striatum (Wittfoth-Schardt et al., 2012). In women, only one study investigated the effect of OXT administration in response to infant stimuli while using fMRI and showed enhanced activation in the VTA in response to pictures of crying (but not to smiling) infants in both nulliparous and postpartum women (Gregory et al., 2015). Enhanced processing of infant faces after OXT administration was also observed in two recent electroencephalography (EEG) studies in both nulliparous women (Rutherford et al., 2017) and mothers (Peltola et al., 2018). Rutherford et al. (2017) found a stronger event-related potential (ERP; P300) in response to infant, but not adult faces after OXT administration. Peltola et al. (2018) observed stronger ERPs toward both infant and adult faces after OXT, whereas this effect was only observed for the N170, an earlier component for which Rutherford et al. (2017) observed no such effect, a difference that might be accounted for by the use of mothers and nulliparous women in the separate studies. Overall, these effects might relate to faster detection of infant faces after OXT, which has recently been observed (Holtfreterich et al., 2016).

Although little can be inferred from these few studies because of different participants groups, methods, and setup, the findings are in line with the general notion derived from animal work that OXT facilitates social reward processing (Bos et al., 2012; Bethlehem et al., 2014; Rilling and Young, 2014; Patin et al., 2018). Work in humans on social reward processing however shows strong person and context dependency (Bartz et al., 2011; Wighton et al., 2015; Wang et al., 2017). For example, although OXT administration increased activation of the VTA during anticipation of social reward (i.e. happy faces) in healthy young women (Groppe et al., 2013) and in police officers with posttraumatic stress disorder (PTSD; Nawijn et al., 2016), it had opposite effects in the control group of the latter study (police officers without posttraumatic stress disorder (PTSD). Also, in a large study investigating the effect of OXT on social cooperation, OXT increased striatal (caudate and putamen) responses to cooperative interactions in men, whereas it decreased such responses in women (Feng et al., 2015). A follow-up study by the same group replicated and extended this finding by also observing reduced VTA responses selectively in women after OXT administration (Chen et al., 2017). These findings further demonstrate the need to take into account such individual differences in OXT administration studies (Bartz et al., 2011; Bos et al., 2012).

With respect to infant caretaking, an important factor that is likely to account for variation in neural responses to OXT is individual variation in caregiving motivation (Buckels et al., 2015; Hofer et al., 2017). Indeed, a recently validated questionnaire that taps into this concept, the Parental Care and Tenderness (PCAT) scale (Buckels et al., 2015) and especially the nurturance subscale (PCAT-n) (Hofer et al., 2017), predicted the motivation to look at infant faces in both parents and nulliparous adults. It has been proposed that care motivation positively relates to neural responses to infant faces (Glocker et al., 2009b; Buckels et al., 2015), but this has not yet been investigated. Therefore, in the current fMRI study we investigated the effect of OXT administration (24 IU) and parental care motivation on neural responses toward infant faces of varying cuteness in nulliparous women. Our paradigm was equivalent to Glocker et al. (2009b) in which nulliparous women were presented with pictures of infant faces that were adapted to have either enhanced or reduced baby schema. This resulted in increased activation of reward-related neural regions in response depending on cuteness condition. Since the current fMRI study is the first to use this paradigm while administering OXT and differences of OXT administration have been observed for participant’s sex and parental status (e.g. Feng et al., 2015; Wighton et al., 2015; Rutherford et al., 2017; Wang et al., 2017; Peltola et al., 2018), only nulliparous women were included, to stay in line with Glocker et al. (2009b). Also, we only included women using oral contraceptives (OCs), as in these women the endogenous cyclic endocrine fluctuations which could interact with OXT administration are absent (Montoya and Bos, 2017).

First, we hypothesized that more pronounced baby schema increases neural activation of reward areas including the VTA and the striatum (caudate, putamen and nucleus accumbens (NAcc)) and that OXT increases this neural activation toward infant stimuli. Second, we hypothesized that these effects depend on individual variation in parental care motivation. Although we focus our analyses on neural regions involved in reward processing, we also included the amygdala, insula and ACC in our analyses. Several studies have observed effects of OXT in these regions in response to social stimuli such as faces (Bos et al., 2012) as well as in response to infant vocalizations such as crying (Riem et al., 2011), demonstrating the potential relevance of these regions for human caregiving behavior (Rilling, 2013; Feldman, 2015).

Materials and methods
Participants
Twenty-six right-handed healthy young nulliparous women were recruited at the university campus of Utrecht University to partake in the study. Only women using combined OCs (i.e. containing ethinylestradiol and levonorgestrel; Microgynon30) were included to avoid hormonal fluctuations during the cycle, and no scans were performed during menstruation (Montoya and Bos, 2017). Participants had no history of psychiatric, neurological, or endocrine abnormalities. Participants did not smoke and used no medication other than OCs. Participants were informed not to drink alcohol or use drugs 24 h and not eat or drink for 1 h prior to study participation. With respect to the drug administration, appointments were rescheduled when participants experienced a blocked or running nose. The experimental protocol was approved by the ethics committee of the University Medical Centre Utrecht and in accordance with the latest declaration of Helsinki. Participants gave written informed consent prior to participation and received payment afterwards. Because of technical problems during the fMRI session (artifacts due to scanner issues, n = 2; malfunctioning of
the presentation software, n = 1) the final sample consists of 23 women (mean age, 20.2; s.d., 1.4, range, 19–24 years).

Procedure
Participants were scanned at the same time of day on 2 separate days with an interval of at least 72 h in a timeframe between 12:00 and 7:00 p.m. Before drug administration (see supplementary online material) participants were screened for alcohol and drug use, were given brief explanations of the task and gave written informed consent.

The participants then self-administered the nasal spray under supervision of the experiment leader and were seated in a waiting room until asked to proceed to the scanner. Participants were screened using an MRI checklist and a metal detector, and were instructed to position themselves on the scanner bed as comfortable as possible and to try to relax. Head movement was minimized by foam pads which were placed between the radiofrequency (RF)-coil and participant’s head. Instructions and task images were displayed on an MRI-compatible monitor positioned at the head end of the scanner visible via an angled mirror attached to the coil. Participants also received a button box in their right hand to rate the cuteness of the infant face. Further instructions during the scan session were given by intercom. Average time interval between OXT administration and the start of the task was 49 min (s.d., 5.8), a time interval consistent with most studies showing effects of OXT on behavior published so far (Bos et al., 2012). After the second session, participants were asked to guess which day they thought they received the OXT. They were not aware which day they received OXT or placebo (binomial: P > 0.05). Finally, participants were debriefed and given payment.

To control whether OXT had any effect on participants’ mood the Positive and Negative Affect Schedule (PANAS; Watson et al., 1988) was filled out twice, once prior to administration upon arrival in the laboratory and once directly before proceeding to the scanner (~30 min after administration). After the second day of testing, the participants received an e-mail to fill out on online versions of the PCAT questionnaire (Buckels et al., 2015) that was used to calculate the nurturance scale (PCAT-n) based on Hofer et al. (2017). The PCAT measures parental care motivation (Buckels et al., 2015) that consists of the conceptually separate constructs nurturance and protection, where the former uniquely predicts sensitivity for infant cuteness, whereas the latter predicts restrictive parenting practices and harsh moral judgments on moral transgressions (Hofer et al., 2017). In the validation study Cronbach’s α of the PCAT-n was 0.88 (Hofer et al., 2017) and for the current sample we obtained a Cronbach’s α of 0.75. Mean score on the PCAT-n was 3.69 (s.d., 0.74; range, 1.83–4.83).

Infant face task and behavioral data analysis
To assess neural responses to infant stimuli we created a task based on Glocker et al. (2009b) in which the participants were presented with infant faces of varying levels of cuteness. The stimuli have been used in previous EEG research (Endendijk et al., 2018) and consisted of nine different pictures of an infant faces (which comprised the normal condition), which were manipulated to create additional low-cuteness and high-cuteness condition of the same face yielding three conditions with a total of 27 stimuli (Borgi et al., 2014). Detailed information on the stimuli can be found in the supplementary online material. A total of 27 stimuli were presented for 3 s in random order twice, resulting in a presentation of 54 stimuli throughout the run, 18 in each condition. Between the stimuli, there was a variable intertrial interval that averaged 5.5 s (min, 3.5; max, 7.5 s) during which a fixation cross was presented. Participants were instructed to carefully look at the stimuli and, after the offset of the face, use the button box in their right hand to rate whether the presented face was ‘not very cute’, ‘cute’, or ‘very cute’. When positioned in the scanner, and directly before the task started, participants received instructions and performed five practice trials. The same task was performed in both test sessions. Stimulus ratings on a three-point scale were included in the fMRI paradigm to guarantee attention of the participants to the stimuli. Additionally, the ratings were used to perform an exploratory behavioral analysis, in which responses on the three-point scale (not very cute: 1, cute: 2, very cute: 3) to the stimuli, as well as reaction times, were averaged per condition and checked for outliers and normality. Reaction times below 200 ms were removed from the data. The data were entered into separate 2 (administration) × 3 (cuteness) analyses of variance (ANOVA). For the statistical analyses of the behavioral data, SPSS 23 (IBM analytics) was used and an α of 0.05 was applied to determine significance throughout the analyses.

fMRI data analyses
Scanning parameters are reported in the supplementary online material. Preprocessing and subsequent analyses were performed with SPM12 (http://www.fil.ion.ucl.ac.uk/spm). Functional scans of both sessions were motion corrected after which the anatomical scan was then coregistered to the mean functional scan. Subsequently, using unified segmentation, the structural scan was segmented and normalization parameters were estimated. Using these normalization parameters, all volumes were normalized to a standard brain template (MNI) and were resliced at 2 mm isotropic voxel size. Smoothing with a 6 mm full width at half maximum Gaussian kernel was applied to the normalized functional volumes. Next, within both sessions, a general linear model (GLM) was applied to the data to investigate the effects of stimulus conditions. Neural responses to the different cuteness conditions were modeled using a 3 s boxcar function convolved with a hemodynamic response function (hrf) as implemented in the SPM12 software. Additional regressors of no interest which are entered into the analyses to reduce unexplained variance in the data include realignment parameters, a discrete cosine transform high-pass filter with a cutoff of 128 s and an hrf-convolved onset of the button press by which the participant rated the stimuli.

The contrast maps of the different cuteness conditions vs baseline in both sessions were entered in a second-level factorial ANOVA, with drug (OXT vs placebo) and stimulus (low, normal and high cuteness) as within-subjects factors. Comparative T-tests were performed to investigate the (de)activations of all stimuli vs rest and the effect of OXT administration. F-tests were run for the effect of cuteness conditions and for the interactions of OXT administrations with cuteness. To control for multiple comparisons in the whole-brain analyses a threshold was set at P < 0.05 [family-wise error (FWE) corrected]. In addition, small volume corrections (SVC; P < 0.05 FWE) were applied for the predefined regions of the interest (ROIs): the amygdala, putamen, caudate, insula and ACC as based on the automated anatomical labeling (AAL) template (Tzourio-Mazoyer et al., 2002). The VTA and NAcc are not included in the AAL template as...
Results

Behavioral data

First, the data were checked for outliers based on the criterion of three times the s.d. above or below the mean in at least one of the conditions. Based on this criterion, one participant was excluded from the analyses on the rating data. Another participant was excluded from the analyses on the reaction times, leaving 22 participants in both analyses. As a next step, normality of the data was checked. For the ratings only the low cuteness condition in the OXT session was not normally distributed \( [D(22) = 0.231, P = 0.004] \). For reaction times, the low-cuteness condition in both drug sessions significantly differed from normality [OXT: \( D(22) = 0.186, P = 0.047 \); placebo: \( D(22) = 0.208, P = 0.015 \)]. Since the assumption of normality was violated for these variables, nonparametric statistical control analyses were performed in addition to the repeated measures ANOVAs.

Analyses on the rating data revealed no effect of administration \( [F(1, 21) = 0.34, P = 0.57, \eta^2 = 0.02] \) or interaction of administration with cuteness condition \( [F(2, 42) = 1.34, P = 0.27, \eta^2 = 0.06] \). There was, however, a significant effect of condition \( [F(2, 42) = 70.82, P < 0.001, \eta^2 = 0.77] \). All five pairwise comparisons between the three conditions were significant (mean rating low cuteness, 1.44; normal cuteness, 1.90; high cuteness, 2.01; all \( P < 0.005 \)), which validated the cuteness categories created by manipulation of the stimuli. Nonparametric control analyses using a Friedman’s ANOVA confirmed the outcome of the ANOVA, by showing a main effect of condition \( [\chi^2 (5) = 64.43, P < 0.001] \), and follow-up Wilcoxon tests showed significant differences between all conditions (all \( z > -2.55 \), all \( P < 0.02 \) but no effects between drug conditions (all \( z < -0.81 \), all \( P > 0.42 \)).

In an additional analysis, we added the PCAT-n as a covariate in the ANOVA. This revealed a significant three-way interaction of the PCAT-n with administration and cuteness condition \( [F(2, 40) = 5.16, P = 0.01, \eta^2 = 0.21] \). This effect was driven by an interaction between condition and the PCAT-n in the OXT condition \( [F(2, 40) = 7.41, P = 0.002, \eta^2 = 0.27] \), which was absent in the placebo condition \( [F(2, 40) = 0.37, P = 0.70, \eta^2 = 0.02] \).
Table 1. Peak T- and F-values, *P*-values, cluster sizes and MNI coordinates for significantly activated voxels

| Experimental effect | Peak voxel location (x, y, z) | T/F-value | Cluster size (Voxels) | P-values |
|---------------------|-------------------------------|-----------|----------------------|----------|
| **Full factorial:** |                               |           |                      |          |
| T-test: stimuli > rest |                               |           |                      |          |
| Lingual gyrus | L −24 −86 −16 | 23.09 | 9870 | <0.001* |
| Fusiform gyrus | L −34 −84 −14 | 22.97 | s.c. | <0.001* |
| Lingual gyrus | R 20 −84 −10 | 22.48 | s.c. | <0.001* |
| Supplementary motor area | L −2 −2 54 | 14.22 | 9747 | <0.001* |
| Precentral gyrus | L −38 −20 56 | 14.00 | s.c. | <0.001* |
| Hippocampus | R 48 −24 52 | 13.55 | s.c. | <0.001* |
| Hippocampus | L −18 −32 −2 | 12.98 | 250 | <0.001* |
| Thalamus | L −12 −22 8 | 7.85 | s.c. | <0.001* |
| Superior parietal lobule | L 28 −54 48 | 11.02 | 1949 | <0.001* |
| Precentral gyrus | L −56 2 34 | 9.91 | 375 | <0.001* |
| Rolandic operculum | L −40 −6 14 | 9.75 | 86 | <0.001* |
| Insula | L −28 24 6 | 8.99 | 273 | <0.001* |
| Calcarine sulcus | L −14 −74 12 | 7.05 | 82 | <0.001* |
| Rolandic operculum | R 40 −4 14 | 6.75 | 20 | <0.001* |
| Fusiform gyrus | R 32 −14 −36 | 6.37 | 25 | <0.001* |
| Calcarine sulcus | R 16 −70 12 | 6.20 | 49 | <0.001* |
| Putamen | L −24 6 2 | 5.82 | 18 | <0.01* |
| Medial frontal cortex | L −46 24 32 | 5.45 | 3 | <0.05* |
| ACC | R 4 2 28 | 4.49 | 21 | <0.01** |
| VTA | L −8 −18 −10 | 4.24 | 110 | <0.01** |
| Amygdala | R 0 −16 −14 | 3.81 | s.c. | <0.05** |

T-test: rest > stimuli |                               |           |                      |          |
| Cuneus | R 10 −86 26 | 10.82 | 713 | <0.001* |
| Angular gyrus | L −44 −74 30 | 9.36 | 721 | <0.001* |
| Middle temporal gyrus | L −56 −6 −16 | 8.47 | 661 | <0.001* |
| Calcarine sulcus | L −26 26 44 | 7.92 | 344 | <0.001* |
| Medial orbitofrontal cortex | R 2 48 −6 | 7.78 | 1179 | <0.001* |
| Lingual gyrus | R 10 −72 −4 | 7.51 | 76 | <0.001* |
| Fusiform gyrus | R 34 −46 −4 | 7.39 | 86 | <0.001* |
| ACC | L −4 54 0 | 7.38 | 315 | <0.001* |
| Amygdala | R 4 26 −6 | 5.89 | 9 | <0.01* |
| Precentral gyrus | R 8 50 8 | 5.15 | 2 | <0.01* |
| Lingual gyrus | L −10 −76 −6 | 7.35 | 41 | <0.001* |
| Middle temporal gyrus | R 58 −6 −20 | 7.06 | 361 | <0.001* |
| Parahippocampal gyrus | L −32 −44 −6 | 6.81 | 115 | <0.001* |
| Medial superior frontal cortex | L −10 64 20 | 6.14 | 54 | <0.001* |
| Inferior parietal cortex | L −58 −40 42 | 6.12 | 61 | <0.001* |
| Precentral gyrus | R 22 −30 64 | 5.68 | 17 | <0.01* |
| Heschl gyrus | R 58 −2 6 | 5.66 | 10 | <0.01* |
| Insula | L −38 −20 −4 | 5.62 | 6 | <0.01* |
| Superior temporal gyrus | L −58 −6 6 | 5.48 | 11 | <0.05* |
| Calcarine sulcus | R 30 −70 6 | 5.38 | 4 | <0.05* |
| Postcentral gyrus | R 22 −40 58 | 5.29 | 3 | <0.05* |

(continued).
Correlational analyses demonstrated that this interaction was caused by a positive correlation of the PCAT-n with ratings in the low-cuteness conditions ($r = 0.25$), but negative correlations in the high cuteness condition ($r = -0.37$). However, these correlations did not reach significance ($P = 0.09$).

Analyses of the reaction times (overall mean, 660.1; s.d., 227.0 ms) showed no significant effect of drug, condition or interaction of drug with condition (all $F$-values $< 0.32$, all $P > 0.73$). Also, Friedman’s ANOVA showed no significant effect for the factor condition ($\chi^2(5) = 1.04$, $P = 0.96$).

To control for a possible effect of OXT administration on participants’ mood, we entered sum scores on the positive and negative scale of the PANAS (Watson et al., 1988) in a 2 x 2 ANOVA with administration and time of measurement (before and after administration) as separate factors. The outcome shows that administration of OXT did not affect scores on these scales—positive scale [$F(1, 22) = 0.04$, $P = 0.85$, $\eta^2 = 0.00$] and negative scale [$F(1, 22) = 0.17$, $P = 0.68$, $\eta^2 = 0.01$]—or interacted with time of measurement—positive scale [$F(1, 22) = 1.24$, $P = 0.28$, $\eta^2 = 0.05$] and negative scale [$F(1, 22) = 3.05$, $P = 0.10$, $\eta^2 = 0.12$]. Overall mean scores on the PANAS were 12.75 (s.d., 2.88) for the negative scale and 33.98 (s.d., 5.77) for the positive scale.

### Imaging data

Whole brain analyses on all participants showed widespread activation across all infant stimuli vs rest, including bilateral visual cortices, hippocampus and sensory-motor areas. Of the

---

**Table 1 (continued).** Peak T- and F-values, P-values, cluster sizes and MNI coordinates for significantly activated voxels

| Experimental effect | Peak voxel location | T/F-value | Cluster size | P-values |
|---------------------|---------------------|-----------|--------------|----------|
| **Region**          | x       | y       | z       | |               |
| Superior frontal cortex | R     | 26      | 22      | 40     | 5.27       | 2         | <0.05*          |
|                      | L     | 60      | −2      | −6     | 5.24       | 1         | <0.05*          |
|                      | R     | 28      | 24      | 44     | 5.24       | 3         | <0.05*          |
| Caudate              | L     | −18     | −6      | 28     | 5.17       | 1         | <0.05*          |
| T-test: placebo > oxytocin | VTA   | R     | 8       | −18    | −20     | 4.00       | 18        | <0.05**         |
|                      | L     | −16     | −16     | −22    | 3.96       | 8         | <0.05**         |
|                      | R     | 26      | 4       | 12     | 3.91       | 19        | 0.05**          |
| Putamen              | R     | 26      | 4       | 12     | 3.91       | 19        | 0.05**          |
| F-test: cuteness condition | VTA   | L     | −4      | −24    | −16     | 9.66       | 5          | <0.05**         |
|                      | R     | 26      | 0       | −22    | 10.24      | 21        | 0.05**          |
|                      | L     | −4      | −18     |        | 10.03      | s.c.      | <0.05**         |

R, right; L, left; s.c., same cluster as above; *whole brain FWE corrected at cluster level, **small volume FWE corrected at cluster level.

**Table 2.** Peak T-values, P-values, cluster sizes and MNI coordinates for significantly activated voxels

| Experimental effect | Peak voxel location | T-value | Cluster size | P-values |
|---------------------|---------------------|---------|--------------|----------|
| **Region**          | x       | y       | z       | |               |
| Full factorial including covariate | VTA   | L     | −16     | −94    | −8      | 7.94       | 39        | <0.001*         |
|                      | R     | 28      | −86     | −14    | 7.45     | 55        | <0.001*         |
|                      | L     | −36     | −88     | −6     | 7.25     | 14        | <0.001**        |
|                      | L     | −22     | −94     | 16     | 7.19     | 122       | <0.001**        |
| Middle occipital cortex | R     | 30      | −88     | 6      | 5.95     | 13        | <0.01*          |
|                      | L     | 14      | −86     | 20     | 5.45     | 2         | <0.05*          |
| Cuneus               | R     | 58      | −26     | 2      | 5.36     | 4         | <0.05*          |
| Superior temporal sulcus | R     | 42      | −18     | 2      | 5.31     | 5         | <0.05*          |
|                     | L     | −42     | −8      | 56     | 5.15     | 1         | <0.05*          |
| Amygdala             | L     | −20     | 0       | −12    | 3.45     | 5         | 0.053**         |
| Insula               | R     | 42      | −16     | 4      | 5.24     | 46        | <0.001**        |
|                      | L     | −42     | −14     | 6      | 4.18     | 17        | <0.05**          |
| Putamen              | R     | 22      | 14      | 6      | 4.21     | 40        | <0.05**          |
|                      | L     | −26     | 6       | 4      | 3.88     | 19        | 0.057**         |
| ACC                  | R     | 2       | 28      | 22     | 4.17     | 22        | <0.05**          |

R, right; L, left; s.c., same cluster as above; *whole brain FWE corrected at cluster level, **small volume FWE corrected at cluster level.
ROIs, the bilateral VTA, amygdala, insula, ACC and putamen all showed significant activation levels, whereas no activation was observed for the caudate and NAcc. Whole brain T-tests comparing the OXT and placebo condition over all cuteness conditions revealed that OXT administration resulted in reduced activation of the bilateral VTA ($P < 0.05$, SVC) and the right putamen ($P = 0.05$, SVC). In addition to this effect of administration, an effect of cuteness condition was observed in the left VTA ($P = 0.05$, SVC) and the right amygdala ($P = 0.05$, SVC; Figure 1C, Table 1). There was no significant increased activity after OXT vs placebo or interaction between OXT administration and cuteness condition in or outside any of the ROIs (Figure 1B, Table 1).

To further qualify and analyze the effects of cuteness in the amygdala and VTA, and drug administration in the VTA and putamen, we extracted the data from the anatomical ROIs and entered these in separate multivariate $2 \times 3$ ANOVAs with administration and condition as within-subjects factors. The results of these analyses confirmed our whole brain analyses (Figure 1), showing a main effect of OXT administration in the VTA [$F(1,22)=9.17, P < 0.01$, $\eta^2_p = 0.29$] and putamen [$F(1,22)=6.98, P = 0.02$, $\eta^2_p = 0.24$] and an effect of cuteness condition on the amygdala [$F(2,44)=5.40, P < 0.01$, $\eta^2_p = 0.20$]. In addition, the analyses on the extracted values also revealed a significant main effect of administration on the amygdala [$F(1,22)=4.59, P = 0.04$, $\eta^2_p = 0.17$], with higher activation in the placebo condition (mean $= 0.116$) compared to the OXT condition (mean $= -0.046$). Post-hoc pairwise comparisons showed that the main effect of condition in the amygdala was caused by a significant difference between responses to the low (mean, $0.093$) and high (mean, $-0.005$) cuteness conditions ($P = 0.01$). The difference between low- and normal-cuteness condition (mean, $0.017$) was not significant ($P = 0.07$), neither was the difference between normal and high cuteness condition ($P = 1.0$). In contrast, the effect of cuteness condition in the VTA, as observed in the whole brain analyses, was not significant in the extracted values. No other main effects or interactions were significant (all $P > 0.1$). Control analyses including order as a between-subjects factor showed no effect of order on the data (all $P > 0.05$) and left the effect of drug unaltered.

Next, we investigated the effect of individual differences in care motivation on the imaging data by adding the PCAT-n scores as a covariate in our whole brain analyses. Higher scores on the PCAT-n were significantly associated with increased neural activation toward all infant stimuli in several regions in the occipital cortex (all $P < 0.001$), the superior temporal sulcus ($P < 0.05$), the insula ($P < 0.001$, SVC), the ACC ($P < 0.05$, SVC) and the putamen ($P < 0.05$, SVC). In the amygdala this association did not reach significance ($P = 0.053$, Table 2). Critically, the PCAT-n also significantly interacted with OXT administration in the putamen ($P = 0.03$, SVC). This was not the case for the other ROIs. To qualify the interaction with OXT administration in the putamen, we computed correlations between individuals’ scores on the PCAT-n and extracted values of the bilateral putamen. This showed a strongly significant positive correlation between the PCAT-n and activation of the putamen toward all infant faces in the placebo condition ($r = 0.60$, $P = 0.003$; Figure 2), which was absent after OXT administration ($r = 0.30$, $P = 0.16$). This relation was significant in all three cuteness conditions after placebo, low ($r = 0.57$, $P < 0.01$), normal ($r = 0.61$, $P < 0.01$) and high ($r = 0.50$, $P < 0.05$), but not after OXT (all $r < 0.42$, all $P > 0.05$). Thus, whereas care motivation was positively associated with neural activation in the insula and putamen, this effect in the putamen was blunted after OXT administration.

**Brain behavior correlations**

Since robust effects of cuteness were only observed in the amygdala, we ran exploratory correlational analyses to investigate whether subjective ratings of the different conditions in the scanner were related to neural activation in the amygdala. Only in the placebo condition, we observed a significant negative relation between subjective ratings and amygdala activation toward infant faces in the high cuteness condition ($r_s = -0.43$, $P = 0.046$). However, these correlational analyses were uncorrected for multiple comparisons and should thus be interpreted with caution.

**Discussion**

The aim of this study was to investigate the effect of OXT on neural reward-related responses to infant faces of varying cuteness in healthy young nulliparous women. The results show that the infant stimuli elicited neural activation in brain areas previously related to reward and salience processing (seeley et al., 2007; Haber and Knutson, 2010; Rilling, 2013; Feldman, 2015), including the VTA, putamen, insula, ACC, and amygdala. Interestingly, no significant activation was observed in the caudate and NAcc, of which especially the NAcc is a core region in the reward pathway (Haber and Knutson, 2010). Furthermore,
activation that was observed in the putamen, insula, ACC, and amygdala was positively related to a validated measure of caregiving motivation, the PCAT-n (Hofer et al., 2017). This relation between participant’s nurturing motivation toward children and neural responses toward infant faces indicates that the current neuroimaging approach is useful in studying underpinnings of human caregiving behavior. Also, subjective ratings of the cuteness of the infant faces validated our manipulation of the baby schema, as all conditions differed in the expected direction (i.e. higher ratings for high-cuteness condition). Nonetheless, we could not replicate a previous finding that the high cuteness condition elicited stronger activation in the reward circuitry (Glockler et al., 2009b), neither did we observe an effect of OXT on the subjective evaluations of the infant faces. We did observe an effect of our baby schema manipulation in the VTA and amygdala, but analyses on the extracted values indicated that the effect in the amygdala was driven by the low-cuteness infants eliciting more activation compared to the high cuteness condition, whereas the effect in the VTA was not significant in the extracted data from the anatomical ROIs (Figure 1). That the stimuli did not elicit activation in the NAcc and caudate and that high cuteness stimuli did not elicitor stronger activation in regions such as the VTA and putamen compared to low or normal cuteness condition might indicate that the neural responses observed do not reflect reward processing only but might relate to more general saliency of the stimuli. Because of conceptual overlap, the neural circuitry involved in saliency detection and reward processing are largely shared, and both contain the ROIs included in the current study such as the VTA, putamen, insula and amygdala (Seeley et al., 2007; Haber and Knutson, 2010). This interpretation is in line with the increased activation for the low-cuteness condition in the amygdala, as that condition is rated as less cute and is also perceived more atypical (demonstrated by additional ratings from an independent group of participants reported in the additional online material), a feature that generally elicits amygdala activation (Todorov et al., 2013). Thus, the infant stimuli elicited the hypothesized subjective responses and neural activation, which related to caregiving motivation, and may reflect overall salience of the stimuli, in addition to the rewarding value that the baby schema have (Kringelbach et al., 2016). Future research could give insight into the specific contribution of cuteness perception, in addition to salience, on activation of the VTA by developing a neuroimaging paradigm in which cuteness and salience can be independently modeled. Comparable to research investigating the neural underpinning of trust evaluations (Todorov et al., 2013), stimuli can be used that vary continuously on cuteness, instead of the categories used in the current study. A similar approach can also be employed to distinguish between cuteness and face typicality. Combining such faces with emotional information during a learning phase before the scan session could then be used to alter the relative salience of part of the stimuli (e.g. Bos et al., 2016).

Critically, the study was set up to investigate the effect of OXT administration on neural responses to infant faces, and our results show reduced activation of the VTA, putamen and amygdala in response to infant faces. Furthermore, in the putamen the reduced activation after OXT administration also attenuated the relation between caregiving motives and putamen activation, which was observed in the placebo condition, but not after OXT administration (Figure 2). This finding could indicate that participants high in caregiving motivation are more susceptible to the effects of OXT, an observation that is in line with literature showing effects of experienced caregiving and representations of adult attachment on sensitivity to OXT administration (Bos, 2017). However, in is unclear why subjects with higher levels of caregiving motivation would show a stronger down-regulating effect in response to infants’ faces after OXT administration. Perhaps the phenomenon of regression to the mean is a more parsimonious explanation for this finding, in that the strongest responses to infant stimuli in the placebo condition are suppressed to the largest extent after OXT administration. Overall, the finding that OXT reduced neural activation in the VTA and putamen was against our predictions. These predictions were based on studies showing positive relations between OXT levels and activation of the ventral striatum toward own infant stimuli in mothers (Strathearn et al., 2009) and increased activation of reward related areas after OXT administration in fathers toward own infant stimuli (Wittfoth-Schardt et al., 2012; Li et al., 2017) and in nulliparous young women toward infant (and erotic) pictures (Gregory et al., 2015).

In retrospect, it might not be surprising that our findings are not in line with the studies in fathers, considering the sex differences that have been observed after OXT administration (Billing et al., 2014; Feng et al., 2015; Wighton et al., 2015; Wang et al., 2017). Although OXT increased activation of the putamen in males during social cooperation, it decreased activation in the putamen and VTA in women (Chen et al., 2017; Feng et al., 2015). The study by Gregory et al. (2015) that found increased activation in the VTA in nulliparous women after OXT administration when observing infant stimuli differed considerably from our current setup. In that study, participants performed a one-back matching task and were presented with stimuli of crying and smiling infant, erotic stimuli and additional stimuli varying in valence, and OXT increased VTA responses only in response to erotic stimuli and crying infants (Gregory et al., 2015). However, subjective ratings by the same participants showed that OXT also increased experienced arousal of the infant stimuli (Rupp et al., 2013). That OXT selectively increased VTA responses toward crying but not smiling infants and that it increased arousal ratings of these stimuli indicate that the VTA responses in that study most likely do not reflect reward responses, but more generally the salience of the stimuli. This might also apply to the first study that demonstrated increased VTA responses after OXT in nulliparous women during anticipation of social reward (Groppe et al., 2013), as in that study OXT had a similar effect during anticipation of punishment.

Irrespective of to what extent the VTA and putamen reflect the reward value of the presented infant faces, it is unclear why the effects of OXT vary between the studies. An important factor could be the emotional arousal inflicted by the stimuli, in which OXT up-regulates VTA and striatal responses toward social stimuli that elicitor arousal (Groppe et al., 2013; Gregory et al., 2015), whereas less arousing reward stimuli, such as in the current stimuli or during social cooperation (Feng et al., 2015; Chen et al., 2017), down-regulate activation of these regions. That this effect also occurs in the context of human caregiving is interesting, as the observation that OXT reduces neural responses related to caregiving motivation nuances the view that OXT would have an overall positive effect on human parental behavior (Feldman, 2015).

In addition to differences in emotional arousal elicited by the stimuli of the current and previous studies, another factor might also have affected variation in neural activation after OXT administration, that is, the use of hormonal contraceptives. In the current study we only included women using combined OCs to control for cyclic endocrine fluctuations, whereas previous studies reporting increased VTA responses after OXT included only naturally cycling women (Groppe et al., 2013;
A recent study that compared naturally cycling women with those using OCs found that in response to pictures of their partner, OXT increased striatal and VTA activation, but only in the naturally cycling women (Scheele et al., 2015). Use of OCs in the current sample might therefore have affected neural responsiveness to the administration, which can occur via down-regulating effects on estradiol and the OXT system (Bos et al., 2012; Bos, 2017). In addition, by down-regulating estradiol, OCs can affect OXT action indirectly by lowering dopamine functioning (Almey et al., 2016; Montoya and Bos, 2017), as dopamine–OXT interactions are considered critical for the role of OXT in the processing of social salience (Shamay-Tsoory and Abu-Akel, 2016). As it is currently unclear to what extent the effect of OXT depends on dopamine and estradiol (e.g. Striepens et al., 2014), methods such as positron emission tomography and spectroscopy should be used to give more insight into the biological mechanisms of OXT administration. Furthermore, it is important that future studies employing an OXT administration paradigm include only naturally cycling women, or at least take the use of hormonal contraceptives into account in the analyses (Montoya and Bos, 2017). More broadly, the effects of OXT on neural responses toward infant faces of varying cuteness should also be investigated in mothers, fathers and nulliparous males, to investigate to what extent the current findings apply to other participant groups.

In addition to the currently observed effects in the VTA and putamen, analyses on the extracted values showed that OXT also attenuated neural responses toward the infant stimuli in the amygdala. Although we are the first to show this effect toward stimuli of infant faces, the effect seems in line with several previous findings of reduced amygdala activation after OXT in women (Bethlehem et al., 2013), also in response to infant stimuli such as crying (Riem et al., 2011). Nonetheless, a recent meta-analyses on studies involving effects of intranasal OXT on amygdala responses to emotional facial expressions found that most studies in women report increased activation of the amygdala after OXT (Tully et al., 2018), and a similar effect was observed for women exposed to socially threatening scenes (Lischke et al., 2012). It thus appears that effects of OXT administration on the amygdala, similar to those on the VTA and striatum, are strongly stimulus dependent. In this respect, future studies can benefit from including face categories other than infants only, to investigate to what extent the currently observed effects of OXT depend on infant faces, or could also be observed in adult faces that vary in cuteness (Peltola et al., 2018), or even in other species (Holtfreterich et al., 2016).

Overall, the current study is the first to report a down-regulating effect of OXT administration on neural responses toward infant faces related to caregiving motivation in nulliparous women. Thereby, it shows that also with respect to caregiving motivation, the effects of OXT may depend on specific personal characteristics (Bartz et al., 2011; Bos, 2017), and as such our findings add to the literature that attempts to specify the role of OXT in how humans process social-emotion information (e.g. Bos et al., 2012; Churchland and Winkielman, 2012; Guastella and MacLeod, 2012; Bethlehem et al., 2014; Shamay-Tsoory and Abu-Akel, 2016; Patin et al., 2018).

**Funding**

The work in this paper was supported by a grant from the Netherlands Society of Scientific Research to P.A.B. (451-14-015).

**Acknowledgments**

We thank Marta Borgi for kindly sharing her stimuli and Maud Buseman and Eline Kraaijenhaver for their help in collecting the data.

**References**

Almey, A., Milner, T.A., Brake, W.G. (2015). Estrogen receptors in the central nervous system and their implication for dopamine-dependent cognition in females. *Hormones and Behavior*, 74, 125–38.

Bartz, J.A., Zaki, J., Bolger, N., Ochsner, K.N. (2011). Social effects of oxytocin in humans: context and person matter. Trends in Cognitive Science, 15, 301–9.

Bethlehem, R.A.I., Baron-Cohen, S., van Honk, J., Auyeung, B., Bos, P.A. (2014). The oxytocin paradox. *Frontiers in Behavioral Neuroscience*, 8, 48.

Bethlehem, R.A.I., van Honk, J., Auyeung, B., Baron-Cohen, S. (2013). Oxytocin, brain physiology, and functional connectivity: a review of intranasal oxytocin fMRI studies. *Psychoneuroendocrinology*, 38, 962–74.

Borgi, M., Cogliati-Dezza, I., Brelsford, V., Meints, K., Cirulli, F. (2014). Baby schema in human and animal faces induces cuteness perception and gaze allocation in children. *Frontiers in Psychology*, 5, 411.

Bos, P.A. (2017). The endocrinology of human caregiving and its intergenerational transmission. *Development and Psychopathology*, 29, 971–99.

Bos, P.A., Jap-Tjong, N., Spencer, H., Hofman, D. (2016). Social context modulates facial imitation of children’s emotional expressions. *PLoS One*, 11, e0167991.

Bos, P.A., Panksepp, J., Bluthe, R.M., Honk, J.V. (2012). Acute effects of steroid hormones and neuropeptides on human social-emotional behavior: a review of single administration studies. *Frontiers in Neuroendocrinology*, 33, 17–35.

Brett, M., Anton, J., Valabregue, R., Poline, J. (2002). Region of interest analysis using an SPM toolbox [abstract]. In: 8th International Conference on Functional Mapping of the Human Brain. Sendai, Japan. Neuroimage, 16.

Buckels, E.E., Beall, A.T., Hofer, M.K., Lin, E.Y., Zhou, Z., Schaller, M. (2015). Individual differences in activation of the parental care motivational system: assessment, prediction, and implications. *Journal of Personality and Social Psychology*, 108, 497.

Chen, X., Gautam, P., Haroon, E., Rilling, J.K. (2017). Within vs. between-subject effects of intranasal oxytocin on the neural response to cooperative and non-cooperative social interactions. *Psychoneuroendocrinology*, 78, 22–30.

Churchland, P.S., Winkielman, P. (2012). Modulating social behavior with oxytocin: how does it work? What does it mean? *Hormones and Behavior*, 61, 392–9.

DeBruine, L.M., Hahn, A.C., Jones, B.C. (2016). Perceiving infant faces. *Current Opinion in Psychology*, 7, 87–91.

Endendijk, J.J., Spencer, H., van Baar, A.L., Bos, P.A. (2018). Mothers’ neural responses to infant faces are associated with activation of the maternal care system and observed intrusiveness with their own child. *Cognitive, Affective, & Behavioral Neuroscience*, 18, 609–21.

Feldman, R. (2015). The adaptive human parental brain: implications for children’s social development. *Trends in Neurosciences*, 38, 387–99.

Feldman, R. (2017). The neurobiology of human attachments. *Trends in Cognitive Sciences*, 21, 80–99.
Feng, C., Hackett, P.D., DeMarco, A.C., et al. (2015). Oxytocin and vasopressin effects on the neural response to social cooperation are modulated by sex in humans. Brain Imaging and Behavior, 9, 754–64.

Glocker, M.L., Langleben, D.D., Ruparel, K., Loughead, J.W., Gur, R.C., Sachser, N. (2009). Baby schema in infant faces induces cuteness perception and motivation for caretaking in adults. Ethology, 115, 257–63.

Glocker, M.L., Langleben, D.D., Ruparel, K., et al. (2009b). Baby schema modulates the brain reward system in nulliparous women. Proceedings of the National Academy of Sciences of the United States of America, 106, 9115–9.

Gorgolewski, K.J., Varoquaux, G., Rivera, G., et al. (2015). NeuroVault. org: a web-based repository for collecting and sharing unthresholded statistical maps of the human brain. Frontiers in Neuroinformatics, 9, 8.

Gregory, R., Cheng, H., Rupp, H.A., Sengelaub, D.R., Heiman, J.R. (2015). Oxytocin increases VTA activation to infant and sexual stimuli in nulliparous and postpartum women. Hormones and Behavior, 69, 82–8.

Groppe, S.E., Gossen, A., Rademacher, L., et al. (2013). Oxytocin influences processing of socially relevant cues in the ventral tegmental area of the human brain. Biological Psychiatry, 74, 172–9.

Guastella, A.J., MacLeod, C. (2012). A critical review of the influence of oxytocin nasal spray on social cognition in humans: evidence and future directions. Hormones and Behavior, 61, 410–8.

Haber, S.N., Knutson, B. (2010). The reward circuit: linking primary anatomy and human imaging. Neuropsychopharmacology, 35, 4.

Hahn, A.C., Perrett, D.I. (2014). Neural and behavioral responses to attractiveness in adult and infant faces. Neuroscience and Biobehavioral Reviews, 46, 591–603.

Hofer, M.K., Buckels, E.E., White, C.J., Beall, A.T., Schaller, M. (2017). Individual differences in activation of the parental care motivational system: an empirical distinction between protection and nurturance. Social Psychological and Personality Science, 1948550617728994.

Holztreich, S.K., Schwarz, K.A., Sprenger, C., Reimers, L., Diedkof, E.K. (2016). Endogenous testosterone and exogenous oxytocin modulate attentional processing of infant faces. PloS One, 11, e0166617.

Kringlebach, M.L., Stark, E.A., Alexander, C., Bornstein, M.H., Stein, A. (2016). On cuteness: unlocking the parental brain and beyond. Trends in Cognitive Sciences, 20, 545–58.

Langlois, J.H., Ritter, J.M., Casey, R.J., Sawin, D.B. (1995). Infant attractiveness predicts maternal behaviors and attitudes. Developmental Psychology, 31, 464.

Leng, G., Ludwigs, M. (2016). Intranasal oxytocin: myths and delusions. Biological Psychiatry, 79, 243–50.

Li, T., Chen, X., Mascaro, J., Haroon, E., Rilling, J.K. (2017). Intranasal oxytocin, but not vasopressin, augments neural responses to toddlers in human fathers. Hormones and Behavior, 93, 193–202.

Lischke, A., Gamer, M., Berger, C., et al. (2012). Oxytocin increases amygdala reactivity to threatening scenes in females. Psychoneuroendocrinology, 37, 1431–8.

Lorenz, K. (1943). Die angeborenen formen möglicher erfahrung. Ethology, 5, 235–409.

Luo, L., Ma, X., Zheng, X., et al. (2015). Neural systems and hormones mediating attraction to infant and child faces. Frontiers in Psychology, 6, 570.

McCullough, M.E., Churchland, P.S., Mendez, A.J. (2013). Problems with measuring peripheral oxytocin: can the data on oxytocin and human behavior be trusted? Neuroscience and Biobehavioral Reviews, 37, 1485–92.

Montoya, E.R., Bos, P.A. (2017). How oral contraceptives impact social-emotional behavior and brain function. Trends in Cognitive Sciences, 21, 125–36.

Montoya, E.R., Bos, P.A., Terburg, D., Rosenberger, L.A., van Honk, J. (2014). Cortisol administration induces global down-regulation of the brain’s reward circuitry. Psychoneuroendocrinology, 47, 31–42.

Nawijn, L., van Zuiden, M., Koch, S.B., Frijling, J.L., Veltman, D.J., Olff, M. (2016). Intranasal oxytocin increases neural responses to social reward in post-traumatic stress disorder. Social Cognitive and Affective Neuroscience, 12, 212–23.

Patin, A., Scheele, D., Hurlenmann, R. (2018). Oxytocin and interpersonal relationships. Current Topics in Behavioral Neurosciences, 35, 389–420.

Peltola, M.J., Strathearn, L., Puura, K. (2018). Oxytocin promotes face-sensitive neural responses to infant and adult faces in mothers. Psychoneuroendocrinology, 91, 261–70.

Riem, M.M., Bakermans-Kranenburg, M.J., Pieper, S., et al. (2011). Oxytocin modulates amygdala, insula, and inferior frontal gyrus responses to infant crying: a randomized controlled trial. Biological Psychiatry, 70, 291–7.

Rilling, J.K. (2013). The neural and hormonal bases of human parental care. Neuropsychologia, 51, 731–47.

Rilling, J.K., DeMarco, A.C., Hackett, P.D., et al. (2014). Sex differences in the neural and behavioral response to intranasal oxytocin and vasopressin during human social interaction. Psychoneuroendocrinology, 39, 237–48.

Rilling, J.K., Young, L.I. (2014). The biology of mammalian parenting and its effect on offspring social development. Science, 345, 771–6.

Rupp, H.A., James, T.W., Ketterson, E.D., Sengelaub, D.R., Ditzen, B., Heiman, J.R. (2013). Lower sexual interest in postpartum women: relationship to amygdala activation and intranasal oxytocin. Hormones and Behavior, 63, 114–21.

Rutherford, H.J., Guo, X.M., Graber, K.M., Hayes, N.J., Pelphrey, K.A., Mayes, L.C. (2017). Intranasal oxytocin and the neural correlates of infant face processing in non-parent women. Biological Psychology, 129, 45–8.

Scheele, D., Plota, J., Stoffel-Wagner, B., Maier, W., Hurlenmann, R. (2015). Hormonal contraceptives suppress oxytocin-induced brain reward responses to the partner’s face. Social Cognitive and Affective Neuroscience, 11, 767–74.

Seeley, W.W., Menon, V., Schatzberg, A.F., et al. (2007). Dissociable intrinsic connectivity networks for salience processing and executive control. Journal of Neuroscience, 27, 2349–56.

Shamay-Tsoory, S.G., Abu-Akel, A. (2016). The social salience hypothesis of oxytocin. Biological Psychiatry, 79, 194–202.

Strathearn, L., Fonagy, P., Amico, J., Montague, P.R. (2009). Adult attachment predicts maternal brain and oxytocin response to infant cues. Neuropsychopharmacology, 34, 2655–66.

Striepens, N., Matusch, A., Kendrick, K.M., et al. (2014). Oxytocin enhances attractiveness of unfamiliar female faces independent of the dopamine reward system. Psychoneuroendocrinology, 39, 74–87.

Todorov, A., Mende-Siedlecki, P., Dotsch, R. (2013). Social judgments from faces. Current Opinion in Neurobiology, 23, 737–80.

Tully, J., Gabay, A.S., Brown, D., Murphy, D.G., Blackwood, N. (2018). The effect of intranasal oxytocin on neural response to facial emotions in healthy adults as measured by functional MRI: a systematic review. Psychiatry Research: Neuroimaging, 272, 17–29.

Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., et al. (2002). Automated anatomical labeling of activations in SPM using a
macroscopic anatomical parcellation of the MNI MRI single-subject brain. *Neuroimage*, 15, 273–89.

Wang, D., Yan, X., Li, M., Ma, Y. (2017). Neural substrates underlying the effects of oxytocin: a quantitative meta-analysis of pharmaco-imaging studies. *Social Cognitive and Affective Neuroscience*, 12, 1565–73.

Watson, D., Clark, L.A., Tellegen, A. (1988). Development and validation of brief measures of positive and negative affect: the PANAS scales *Journal of Personality and Social Psychology*, 54, 1063.

Wigton, R., Jocham Radua, P.A., Averbeck, B., et al. (2015). Neurophysiological effects of acute oxytocin administration: systematic review and meta-analysis of placebo-controlled imaging studies. *Journal of Psychiatry & Neuroscience: JPN*, 40, E1–22.

Wittfoth-Schardt, D., Grunding, J., Wittfoth, M., et al. (2012). Oxytocin modulates neural reactivity to children’s faces as a function of social salience. *Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology*, 37, 1799–807.